about
Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemiaHigh cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment.Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia.Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation.Successful treatment of Acremonium fungemia with voriconazole.NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey.Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience.Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma.Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trialsPeripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical studyBortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatmentExpansion of B cell precursors after unrelated cord blood transplantation for an adult patientInvasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk?Long-term results of rituximab treatment for membranous nephropathy after allogeneic hematopoietic SCT: a case report
P50
Q35669875-67C4DEE6-A5C1-4D48-8DCA-71D20AB8F428Q37273182-345C77F9-77CA-45AF-AAFE-FAD866EFD95FQ37597610-C06D22E1-7914-49E8-8569-C7F4750EF3B9Q38384261-24F8617B-AEC7-42C8-A6AF-8EBCD9FCE422Q38568955-C9E4627E-8250-48E2-AAA3-67C278990E6CQ42974471-6B209655-D7EC-4F45-B835-0760F8EEEC87Q42981949-3BCBCA14-31D7-4640-95F0-9E3AC5672C19Q44245132-1EA97CBF-7A81-476F-9347-24FA06089E33Q44671020-A8032F84-8626-47B3-81A6-99CF3A9DB0A6Q44862538-DC6553F3-2447-43E3-8198-491A890CD3BCQ51112125-C18D3345-5455-4FB2-A7C9-BC4E8D9E7743Q52856072-181EB303-E96F-468D-B19A-A11D189BB292Q53248862-4FE3FE50-1F27-4A94-B51F-04C43C6F095EQ60171402-2AF6A56A-2F10-4F2D-80B3-F4555C24197DQ61774252-772A28C7-A11D-4152-B589-7FCD8AA1EC42Q80027704-E3438681-D86D-4867-BF28-F36F3E1DF368Q80387219-4C9C6264-B1C3-47AF-9F5B-3364E8A0749DQ81291574-865CA844-352B-47F8-B224-D45C7C5FE9DBQ84590141-C0DC5A95-CF5C-44C0-B7F9-F52206BD9BE1
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniele Mattei
@ast
Daniele Mattei
@en
Daniele Mattei
@es
Daniele Mattei
@nl
Daniele Mattei
@sl
type
label
Daniele Mattei
@ast
Daniele Mattei
@en
Daniele Mattei
@es
Daniele Mattei
@nl
Daniele Mattei
@sl
prefLabel
Daniele Mattei
@ast
Daniele Mattei
@en
Daniele Mattei
@es
Daniele Mattei
@nl
Daniele Mattei
@sl
P106
P1153
7004315458
P31
P496
0000-0003-3152-4416